Online Disruptive Technologies Announces Publication of Results in Cancer Journal
LAS VEGAS, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Online Disruptive Technologies, Inc. (OTC PINK:ONDR) (the “Company”) is pleased to announce that its lung cancer clinical study results were published in the scientific journal Cancer Immunology and Immunotherapy. The results as published clearly validate the promise of Savicell’s Liquid ImmunoBiopsy™. The published study uses the Savicell Diagnostics, Ltd. platform to diagnose lung cancer, producing 91% sensitivity and 80% specificity in a 20-fold cross-validation. Diagnosis of Stage 1 lung cancer is as accurate as later stages.
The study is entitled “Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles” by Adir, Y., Tirman, S., Abramovitch, S. et al. Cancer Immunol Immunother (2018). https://doi.org/10.1007/s00262-018-2173-5 and the publication can be accessed here: https://link.springer.com/article/10.1007%2Fs00262-018-2173-5
Savicell™ has a first-in-class liquid ImmunoBiopsy™ platform designed for the early detection of disease. The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. The Savicell™ Well-Shield™ platform is a blood test inherently designed for the early detection of disease. The Company’s initial focus is on the multi-billion dollar, underserved cancer liquid biopsy market. Contact: Giora Davidovits 978-289-9056 Info@savicell.com
Notice Regarding Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our technology is designed to be deployed for early detection of diseases; that our technology may have additional applications in drug response monitoring for therapies that impact immune response, that the Well-Shield™ technology is designed to detect and interpret differential metabolic responses; and that we have patent protection on our technology. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug and treatment discovery and development, which include, without limitation, the potential failure of development candidates to advance through clinical studies or demonstrate safety and efficacy in clinical testing; our ability to retain key employees; our ability to finance development; and our ability to satisfy the rigorous regulatory requirements for new medical procedures. Good results in small trials and among limited cases does not necessarily lead to the same good results for large numbers or in the general public. Competitors may develop better or cheaper alternatives to our products. Having patented technology does not guarantee that our patents may not be challenged, or that we may be infringing on the intellectual property of others. We may not be able to commercialize our product and even if we do, we may not realize any profit. The potential market may be much smaller than expected. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this press release to reflect events or circumstances after today’s date. Readers should also refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.